News of the day
Middle income group to pay Rs 20,000 for case
in Supreme Court
New
Delhi: In some good news, middle income group people can get their cases argued
in the Supreme Court for a nominal fee of not more than Rs 20,000.Â
To fulfil the requirement the annual gross salary should not exceed Rs 7.5 lakh or and the monthly income Rs 60,000.Â
The scheme is available under the Supreme Court Middle Income Group Legal Aid Society, which is headed by a sitting judge of the Supreme Court with the Attorney General of India as its ex-official vice president.Â
To fulfil the requirement the annual gross salary should not exceed Rs 7.5 lakh or and the monthly income Rs 60,000.Â
The scheme is available under the Supreme Court Middle Income Group Legal Aid Society, which is headed by a sitting judge of the Supreme Court with the Attorney General of India as its ex-official vice president.Â
Disclosing
this at a news conference here on Monday, office bearers of the society and
senior counsel Ranjit Kumar and Raju Ramachandran, said middle class people who
can't afford the expensive litigation in the Supreme Court can avail the
services of the society for a nominal amount. The society comprises 30
prominent senior advocates, besides 100-odd advocates on record.Â
Counsel Ravindra Bana and president of the Supreme Court Advocates on Record Association Sushil Kumar Jain were also present at the press meet.Â
Counsel Ravindra Bana and president of the Supreme Court Advocates on Record Association Sushil Kumar Jain were also present at the press meet.Â
As per the Supreme Court rules it is only through
advocates on record cases can be filed before it.Â
According to Ranjit Kumar, any person desirous of availing the services of an advocate empanelled under the scheme will have to approach the secretary of the society by filing an application. The society's office is located at 109, Lawyers Chambers, Post Office Wing, located within the Supreme Court complex.Â
Under the scheme even a senior advocate if engaged by a client can charge a maximum of Rs 9,000 for three days of hearing or for the entire case. The amount would start from as low as Rs 3,000 depending upon the stage of the petition at which it is argued.Â
The counsel said that though the scheme was in vogue since 1995, the general public was not aware of it. Hence, efforts are being made to create awareness among the general public on the beneficial scheme.Â
According to Ranjit Kumar, any person desirous of availing the services of an advocate empanelled under the scheme will have to approach the secretary of the society by filing an application. The society's office is located at 109, Lawyers Chambers, Post Office Wing, located within the Supreme Court complex.Â
Under the scheme even a senior advocate if engaged by a client can charge a maximum of Rs 9,000 for three days of hearing or for the entire case. The amount would start from as low as Rs 3,000 depending upon the stage of the petition at which it is argued.Â
The counsel said that though the scheme was in vogue since 1995, the general public was not aware of it. Hence, efforts are being made to create awareness among the general public on the beneficial scheme.Â
Free medicines for all at public health
facilities soon
: Monday, September 17, 2012,21:04
Despite a scaled-down outlay of 1.95 per cent of GDP during the 12th Plan, Health Ministry officials say none of its planned schemes will be sacrificed and it is keen to launch the free medicines project soon."We should be able to work out all our schemes within the budget earmarked for the 12th Plan. No scheme will be sacrificed," a top Health Ministry official told PTI.
He said, "We are keen to launch the free medicine scheme within the next two months. The effort is to launch it from November 1 and the model of Rajasthan Medical Services Corporation and that of Tamil Nadu, which has been a pioneer in this, are being studied."Once the scheme is launched, the government will provide free generic medicines to all patients coming to public health facilities - from primary and community health centres to district hospitals and medical colleges.
The Health Ministry intends to earmark an amount of Rs 2,000 crore annually under the proposed National Health Mission (NHM) for supplementing the states` resources under the scheme, which will see its scaling up to Rs 6,000 crore for augmenting the supply chain management of medicines.
While the Centre will supplement the states` efforts, the Health Ministry is mandating that besides creating a list of generic medicines, states should prepare standard treatment guidelines and evolve a system of procurement.
The Ministry has favoured that medicines be procured centrally and their stocks be maintained which will help in drastic reduction in the cost of such medicines. Officials said by doing so, like in Rajasthan, there can be reduction in cost of medicines by up to 70 per cent.
For the success of the project, the Centre is also pressing for prescription of generic medicines and ensuring that their quality is maintained through proper testing of drugs, besides developing a grievance redressal mechanism.
Adequate supply of essential medicines at health centres has been an area of concern, with even the performance audit of National Rural Health Mission pointing to glaring deficiencies in the drug supply chain at health centres across India.
So much so so that the CAG found expired drugs being supplied to patients at some places, defeating the very purpose of the scheme.
During a performance audit of NRHM in 2008, the CAG had found essential medicines in short supply at a number of test -checked health centres.The CAG also found that the NRHM provision of two month medicine stock at a health centre was not being adhered to in most places.
As many as 13 states including Assam, Delhi, Haryana, J&K, Punjab and Jharkhand had not cared to prepare the common formulary of essential drugs that should be available at a health centre, the CAG report said.
The free medicines scheme being evolved now will finally take the ministry towards universal health care for all. The scheme aims to help reassert the faith of the common man in public health facilities, which the Ministry intends to strengthen across the country during the 12th Plan.
PTI
A REPORT FROM DECCAN CHRONICLE--- DOCTORS
ARE PAMPERED BY PHARMA COMPANIES
In India, gift-giving drives drugmakers' marketing
- September 17,
Sales
representatives for Abbott Laboratories Inc's Indian subsidiaries know what it
takes get a doctor to prescribe the drugs they market: a coffee maker, perhaps,
or some cookware, or maybe a vacuum cleaner.
These are
among the many gifts for doctors listed in an Abbott sales-strategy guide for
the second quarter of 2011. As laid out explicitly in the guide, doctors who
pledge to prescribe Abbott's branded drugs, or who've already prescribed
certain amounts, can expect some of these items in return.
Consider
the guide's entry for Nupod, an Abbott antibiotic generically known as
cefpodoxime. It lists a medical textbook, a mosquito repellant and a coffee
maker as incentives for doctors.
It also
provides a script of the social niceties for clinching the quid pro quo:
"Dr presenting you advanced coffee maker from Philips which will make
coffee within three minutes. Dr in the box we have made advancement easy for
you by giving the ideal usage guidelines of the coffee maker. Dr I look forward
for advancement in action i.e. our Nupod brand. Dr can get just 3 Rx per day
for Nupod."
Especially
in India's poorer areas, says one Abbott rep, "if you give them a small
gift, they are happy."
A larger problem
The
Abbott guide - reps say the company produces them regularly - is evidence of a
larger problem in India. Dozens of doctors, drug reps and other healthcare
insiders said domestic and multinational drug makers routinely shower Indian
doctors with gifts, posh junkets abroad, and cash payments disguised as
consultancy or other types of fees.
"Indian
CRM," or customer-relationship management, is what industry insiders call
this system of inducements. None of the doctors or reps who described their
participation in this trade would speak on the record. Under Indian law, doctors
are prohibited from accepting cash, gifts or travel from drug companies. Still,
enforcement is rare, and drug makers may lavish gifts on doctors with impunity,
though their home countries may punish the practice.
In a
country where doctors often make less than $10,000 a year, it can be an
effective strategy.
"Somebody
is doing something for you," says a Delhi-based cardiologist.
"Obviously you will want to return the favor." He says he prescribes
more drugs from companies that provide gifts and send him on paid vacations to
Thailand, Hong Kong and elsewhere. One of those companies, he says, is the
India-based Ranbaxy unit of Japan's Daiichi Sankyo Co.
"We
do not sponsor vacations for doctors," a Ranbaxy spokesperson said.
"We are viewed as a scientifically and academically orientated company and
our promotional activities are built around academics and science."
Chicago-based
Abbott said that it complies with local laws and regulations in India. It added
that company policy forbids employees to "offer or give a sponsorship,
gift, meal or entertainment in exchange for an explicit or implicit agreement
that Abbott Products will be used, purchased, ordered, recommended or
prescribed or that Abbott or any Abbott products will receive any favorable
treatment."
So many choices
The
Indian market is particularly vulnerable to corruption because of the intense
competition here. Until 2005, India flouted drug patents, refusing to rein in
domestic copycats of Big Pharma's blockbusters. Brands proliferated. Today, an
Indian doctor can choose from among 224 registered brands of the
cholesterol-lowering drug atorvastatin, sold by Pfizer Inc as Lipitor in the
U.S. and elsewhere.
Foreign
companies that want a piece of this crowded market "have to adapt, or they
are not going to survive," says an executive with Biocon, a leading Indian
biotech company. The executive says Biocon routinely gives doctors iPads,
iPods, mobile phones, "you name it."
A Biocon
spokesperson said the executive's statements are "incorrect and absolutely
untrue" and added that the company operates "in strict
compliance" with the law.
Public
health experts and some Indian doctors say that as a result of drug companies'
tactics, drugs are dangerously overprescribed and expensive brands are
prescribed instead of cheap ones. That can be devastating for patients --
physically and financially -- in a country where health care is mostly private
and unsubsidized and 400 million people live on less than $1.25 a day.
At the
Amrita Clinic, a private practice in Pune, Maharashtra State, physician Vinay
Kulkarni says he refuses to accept gifts from reps, in part because he believes
drug makers overcharge for their products to recoup marketing expenses.
"Ultimately," he says, "everything is being paid by the
patient."
As Big
Pharma has pushed into emerging markets like India in recent years, companies
have been running into trouble with their home-market overseers. Many of the
world's top drug makers have warned in recent regulatory filings of potential
costs related to charges of corruption in foreign markets.
Tea sets in China
Last
year, Johnson & Johnson agreed to pay $70 million to settle U.S. charges
that it paid bribes and kickbacks to win business in Greece, Iraq, Poland and
Romania. Pfizer Inc recently agreed to pay $60.2 million to settle a U.S.
government probe of the drug maker's use of illegal payments to win business
overseas, including gifts such as cellphones and tea sets to doctors in China
who prescribed the company's products.
Abbott
became the No. 1 pharmaceuticals company in India in 2010, when it paid $3.7
billion for the branded generics business of Mumbai-based Piramal Healthcare.
Its thousands-strong Indian sales force has helped buoy the parent, as sales in
emerging markets rose 23 percent to $2.59 billion in the second quarter of 2011
-- more than twice Abbott's global growth rate.
Reps from
Abbott True Care, Abbott Healthcare and Abbott Primary Care - all formerly part
of Piramal and now subsidiaries of Abbott -- say sales plans are revealed to
them at "cyclical sales meetings" every three or four months. These
meetings, they say, sometimes include studying printed strategy guides like the
one for second-quarter 2011 that Reuters reviewed.
That
guide offers no clarity on why particular gifts are paired with particular
drugs. None of the items that come with Nupod, the antibiotic, go to doctors
who prescribe Pantagon IT. That drug - a combination of itopride, for bloating
and indigestion, and the antacid pantoprazole - comes with a stapler, a set of six
glasses and a jar from Luminarc, and a Forbes Trendy Nano vacuum cleaner.
"THE
PANTA REWARDS INPUTS MUST ONLY BE PRESENTED AT THE DRS HOME," the guide
tells reps. When delivering the glassware, reps are instructed to say,
"Thus Dr requesting your continuous prescription support for Pantagon
IT."
Prescriptions
for Paraxin, a drug for typhoid fever, are rewarded with a hand sanitizer and
an antique pen. Prescriptions for Lysupra, a multivitamin supplement, could
earn a beaded car-seat cover "for the relaxation when you are
traveling."
Depending
on the drug, a doctor might find himself the owner of a Kiwi shoeshine kit, an
Ambi Pur car air freshener, a Birla steam iron, or a Pure Relaxation CD series.
And if that's not enough, participation in a "Doctor Talent Contest"
judged by Bollywood actor Boman Irani might seal the deal.
Scanners and steam irons
Abbott
reps say that so far this year, they have doled out, among other things,
scanners, steam irons, shoes, stethoscopes and gift vouchers worth more than
$100 to doctors - both private and government-employed.
Amitava
Guha, a member of the national working committee of the Federation of Medical
and Sales Representatives' Associations of India, worked as a rep for decades,
including for Piramal from 1997 to 2008, when he retired. "Everybody is
doing it," he says. "I was doing it when I was in service.... They
said that it is your job to go and give to the doctors."
He says
he resisted giving anything but the smallest gifts, like pens. Today, he says,
he receives frequent complaints from reps across the country about the
practice. It taints their professional image, he says. Also, it's hard work
toting around all those gifts. "They have been given huge extra bags to
carry," he says. "One on the shoulders and two others in the
hands."
The
managing director of a large diabetes clinic in Calcutta says he sees as many
as 25 reps a day. "Whatever you like, they can provide you," this
doctor says.
His
interview with Reuters was interrupted when a man squeezed into his office and
placed a big yellow box on the table. "Sir, this is an exquisite casserole
set," the visitor said, slipping the doctor a note bearing the brand name
Rostar, a cholesterol-lowering medicine from Mumbai-based Unichem Laboratories
Ltd.
Unichem
did not respond to requests for comment.
Guha, the
union federation official, says that reps have begun reporting a shift in
emphasis away from the types of gifts listed in Abbott's guide toward free
"foreign tours" and outright cash payments, often made under the
guise of public health initiatives or research.
Every
year, Abbott, collaborating with doctors and other groups, conducts hundreds of
"health camps" across India to raise awareness about conditions such
as diabetes, high cholesterol, anemia, breast cancer, sleep problems and
thyroid disease.
Abbott
says these programs "generally incorporate diagnosis, prevention and
education. � The focus of these camps is around disease and not
products."
In the name of science
Reps say
public health isn't always the point. "This is a business
transaction," says one. This rep says that at a diabetes camp he worked
on, patients were given random blood-sugar tests - not a valid means of
diagnosing diabetes - and based on the result, were prescribed Abbott oral
diabetes medications by the participating doctor.
Similarly,
reps and doctors say companies try to boost sales through so-called
non-interventional post-marketing studies, commonly used around the world to
monitor the safety and efficacy of drugs after they have been approved for
sale.
Doctors
and reps say that often, companies use these studies as cover for paying
doctors to prescribe the drugs under study. According to one Abbott rep, the
company doesn't pay doctors if sales at nearby pharmacies don't increase.
A doctor
who has done post-marketing studies in India says the companies rarely monitor
the studies or check the data. "We all understand that post-marketing
studies are not really true studies," says the doctor, a diabetes
specialist at a Calcutta hospital. They're "just a way to offer an
honorarium. So we also don't take them seriously."
Comments